- Castle Biosciences ( NASDAQ: CSTL ) said it expects to meet or exceed the top end of its previously guided range of $132M-$137M million for full-year 2022 total revenue vs. consensus at $135.6M.
- The company delivered 12,563 total test reports in the fourth quarter of 2022, compared to 8,242 in the same period of 2021, an increase of 52%.
- It expects growth of 37% year over year in DecisionDx ® -Melanoma test report volume.
- Total test reports delivered in 2022 were 44,338, compared to 28,118 in the same period of 2021, an increase of 58%.
- Year-end 2022 cash and cash equivalents are expected to be ~$123M.
- Additionally, the company expects to hold ~$136M in short-term investments.
For further details see:
Castle Biosciences expects to meet or exceed guided FY22 revenue of $132M-$137M